Clinical Scorecard: Next-generation Graft Health Monitoring

At a Glance

Key Highlights

• Acute graft rejection occurs in 30-45% of heart transplant patients.
• dd-cfDNA offers a non-invasive alternative to endomyocardial biopsy.
• High negative predictive value (97%) of dd-cfDNA makes it an ideal rule-out test.
• Standardization of dd-cfDNA cut-offs is needed across laboratories.
• Financial and structural barriers hinder the adoption of dd-cfDNA testing.

Guideline-Based Recommendations

Diagnosis

• Use dd-cfDNA as a non-invasive marker for acute graft rejection.

Management

• Transition from invasive biopsies to dd-cfDNA blood tests for monitoring.

Monitoring & Follow-up

• Monthly monitoring of dd-cfDNA levels in the first year post-transplant.

Risks

• Invasive procedures carry risks; dd-cfDNA testing reduces these.

Patient & Prescribing Data

Heart transplant recipients

dd-cfDNA testing could streamline post-transplant care and reduce patient burden.

Clinical Best Practices

• Implement high-quality cell-free DNA extraction methods.
• Utilize next-generation sequencing for accurate dd-cfDNA measurement.
• Establish a robust quality assurance framework for decentralized testing.

References

• Next-generation Graft Health Monitoring